Cargando…

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer

PURPOSE: Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the RAS genes beyond KRAS exon 2. We performed extended RAS Mutational analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dalyong, Hong, Yong Sang, Kim, Jeong Eun, Kim, Kyu-pyo, Lee, Jae-Lyun, Chun, Sung-Min, Kim, Jihun, Jang, Se Jin, Kim, Tae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266405/ https://www.ncbi.nlm.nih.gov/pubmed/27121720 http://dx.doi.org/10.4143/crt.2016.069

Ejemplares similares

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer
por: Svedlund, Jessica, et al.
Publicado: (2019)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Rise of the specialized onco-ribosomes
por: Kampen, Kim R., et al.
Publicado: (2018)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment
por: Kim, Hyung-Don, et al.
Publicado: (2022)

Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
por: Kim, Seong-Ryong, et al.
Publicado: (2021)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Metastatic cells: moving onco-targets
por: Patsialou, Antonia, et al.
Publicado: (2014)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018)

Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping
por: Shin, Su-Jin, et al.
Publicado: (2017)

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
por: Vivancos, Ana, et al.
Publicado: (2019)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations
por: Maeng, Chi Hoon, et al.
Publicado: (2012)

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer
por: Xu, Xiaojing, et al.
Publicado: (2023)

Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation
por: Ganesan, Lakshmi, et al.
Publicado: (2017)

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
por: García-Foncillas, Jesús, et al.
Publicado: (2018)

2020 Korean guidelines for the management of metastatic prostate cancer
por: Kim, In-Ho, et al.
Publicado: (2021)

Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer
por: Kim, Kyu-pyo, et al.
Publicado: (2017)

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
por: Choi, Yeonjoo, et al.
Publicado: (2019)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
por: Wu, Bin, et al.
Publicado: (2017)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
por: Toledo, Rodrigo A., et al.
Publicado: (2016)

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
por: Manzanares-Martin, Barbara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_srmvdi48objguoglp8db28s8ue